Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2083830 | 0.84 | DGAT1 (0.37) | DGAT1BRD4CREBBP | |
| SCHEMBL3529044 | 0.75 | DGAT1 (0.37) | DGAT1F2RL1 | |
| SCHEMBL3640273 | 0.74 | DGAT1 (0.39) | DGAT1BRD4CREBBP | |
| SCHEMBL3635281 | 0.74 | DGAT1 (0.35) | DGAT1BRD4CREBBP | |
| SCHEMBL20552342 | 0.74 | DGAT1 (0.37) | DGAT1BRD4CREBBP | |
| SCHEMBL20553092 | 0.74 | DGAT1 (0.37) | DGAT1BRD4CREBBP | |
| SCHEMBL30280095 | 0.73 | BRD4 (0.35) | DGAT1BRD4CREBBP | |
| SCHEMBL30280225 | 0.73 | DGAT1 (0.34) | DGAT1BRD4CREBBP | |
| SCHEMBL20552062 | 0.73 | BRD4 (0.39) | DGAT1BRD4CREBBP | |
| SCHEMBL31463300 | 0.72 | DGAT1 (0.37) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858652-B2 | Substituted 4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858652-B2 | Substituted 4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| CN-101535298-A | Substituted 4-imidazoles | HOFFMANN LA ROCHE (CH) | 2009-09-16 | — | — | CN | disclosed |
| EP-2084152-A2 | SUBSTITUTED 4-IMIDAZOLES | F. Hoffmann-Roche AG (CH) | 2009-08-05 | — | — | EP | disclosed |
| US-20080139533-A1 | SUBSTITUTED 4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
| US-20080139533-A1 | SUBSTITUTED 4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
| WO-2008058867-A2 | SUBSTITUTED 4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139533-A1 | SUBSTITUTED 4-IMIDAZOLES | TAAR1, TAAR5, TACR1 | DGAT1 3361/4885BRD4 1242/4885CREBBP 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.